Skip to main content

Table 1 Frequency of heterozygosity and LOH in breast cancer and other cancer tissue

From: Androgen receptor CAG repeats, non-random X chromosome inactivation, and loss of heterozygosity at Xq25 in relation to breast cancer risk

Sample Breast Cancers (BC) Other Cancers (OC) P
marker Heterozygosity/No. of BC Heterozygosity % LOH/informativea LOHb % LOH/informative LOH % valuec
DXS8067 29/65 44.6% 13/29 44.83% 5/17 29.4% 0.47
DXS1001 56/65 86.2% 17/56 30.36% 6/19 31.6% 0.85
DXS8059 34/65 52.3% 13/34 38.24% 1/8 12.5% 0.17
DXS8098 46/64 71.9% 13/46 28.24% 7/17 14.1% 0.50
DXS8009 50/64 78.1% 14/50 28.00% 6/16 37.5% 0.68
DXS1047 55/65 84.6% 26/55 47.23% 5/20 25.0% 0.14
DXS8068 49/65 78.5% 20/51 39.22% 5/16 31.2% 0.78
DXS8078 20/59 33.9% 4/20 20.00% 1/14 7.1% 0.379
DXS8071 13/58 22.4% 4/13 30.77% 0/14 0.0% 0.041
DXS8041 46/58 79.3% 9/46 19.57% 4/21 19.0% 0.676
DXS8074 32/58 55.2% 11/32 34.38% 2/15 13.5% 0.175
Xq25    46/65 70.7% 10/25 40.0% 0.014
  1. The frequency of heterozygosity and LOH in the breast cancers (BC) and other cancers (OC) are presented in this table.
  2. a. informative: patients with heterozygosity.
  3. b. LOH %: number of patients with LOH divided by number of patients with heterozygosity.
  4. c. Chi-square test and Fisher’s exact probability test.